Elicio Therapeutics (ELTX) Accounts Payables (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Accounts Payables data on file, last reported at $272000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 93.26% year-over-year to $272000.0; the trailing twelve-month figure through Mar 2026 stood at $272000.0 (down 93.26% YoY), and the FY2025 full-year result was $672000.0, down 35.26% from the prior year.
• Accounts Payables for Q1 2026 stood at $272000.0, down from $672000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $4.4 million in Q3 2023 and bottomed at $272000.0 in Q1 2026.
• The 5-year median for Accounts Payables is $2.2 million (2022), against an average of $2.3 million.
• The widest annual swing landed in 2025, when Accounts Payables jumped 266.35%; it then plunged 93.26% in 2026.
• A 5-year view of Accounts Payables shows it stood at $2.8 million in 2022, then surged by 55.76% to $4.4 million in 2023, then tumbled by 76.24% to $1.0 million in 2024, then slumped by 35.26% to $672000.0 in 2025, then slumped by 59.52% to $272000.0 in 2026.
• The last three Accounts Payables figures came in at $272000.0 (Q1 2026), $672000.0 (Q4 2025), and $321000.0 (Q3 2025), per Business Quant data.

Peer Comparison